The effects of Δ12-PGJ2 on malignant cells

Prostaglandins and Other Lipid Mediators

Volumn 62, Issue 1, 2000, Pages 75-90

  Mc Clay, Edward F ^a  

^a Department of Radiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CISPLATIN; CYCLIN B; CYCLIN D1; CYCLIN E; CYCLOPENTENONE DERIVATIVE; DELTA12 PROSTAGLANDIN J2; DNA FRAGMENT; PROSTAGLANDIN D2; PROSTAGLANDIN DERIVATIVE; PROTEIN BAX; PROTEIN P53; 9-DEOXY-9,10-DIDEHYDRO-12,13-DIDEHYDRO-13,14-DIHYDROPROSTAGLANDIN D2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL LINE; CYTOTOXICITY; HUMAN; MELANOMA CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; CELL CULTURE;

ANIMALS; HUMANS; PROSTAGLANDIN D2; TUMOR CELLS, CULTURED;

EID: 0033624524     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(00)00076-9     Document Type: Article

References (47)

1. 2 formation by malignant melanoma cells correlates inversely with cellular metastatic potential. Proc Natl Acad Sci. 76:1979;1765-1769.
2. 2 controls metastasis of malignant melanoma cells. Nat. 282:1979;76-78.
3. 2. Prostaglandins. 25:1983;47-54.
4. 2 in human and murine melanoma cells in culture. Cancer Res. 46:1986;1688-1693.
5. 2 formed in human plasma. Proc Natl Acad Sci. 81:1984;1317-1321.
6. 2 derivitive with potent antineoplastic activity and weak sooth muscle-contracting activities. Biochem Biophy Res Comm. 109:1982;626-633.
7. 2 identification of products formed in vitro. J Biol Chem. 258:1983;11713-11718.
8. 2 exerting cell growth inhibition. Biochem Biophy Res Comm. 127:1985;739-745.
9. Narumiya S., Fukushima M. Site and mechanism of growth inhibition by prostaglandins. I. Active transport and intracellular accumulation of cyclopentenone prostaglandins, a reaction leading to growth inhibition. J Pharmacol Exp Ther. 239:1986;500-505.
10. Narumiya S., Ohno K., Fujiwara M., Fukushima M. Site and mechanism of growth inhibition by prostaglandins. II. Temperature-dependent transfer of a cyclopentenone prostaglandin to nuclei. J Pharmacol Exp Ther. 239:1986;506-511.
11. 2 in nuclei. J Pharmacol Exp Ther. 242:1987;306-311.
12. Ohno K., Fukushima M., Fujiwara M., Narumiya S. Induction of 68 000-dalton heat shock proteins by cyclopentenone prostaglandins. J Bio Chem. 263:1988;19764-19770.
13. Santoro M.G., Garaci E., Amici C. Prostaglandins with antiproliferative activity induce the synthesis of a heat shock protein in human cells. Proc Natl Acad Sci. 86:1989;8407-8411.
14. Santoro M.G., Garaci E., Amici C. Induction of heat shock protein synthesis by prostaglandins with antineoplatsic and antiviral activity. Adv Prostaglandin Thromboxane Leukotriene Res. 21:1990;867-874.
15. 2 results in elevated expression of gadd 153 mR NA. Exp Cell Res. 199:1992;85-89.
16. Fornace A.J., Nebert D.W., Hollander C., et al. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol Cell Bio. 9:1989;41906-44203.
17. 2 in human P1-21 myeloid leukemia and RC-K8 pre-B lymphoma cells. Prostaglandins. 52:1996;143-156.
18. Fukushima M, Sasaki H, Fukushima S. Prostaglandin J2 and related compounds: mode of action in G1 arrest and preclinical results. Ann NY Acad Sci 1994;161-5.
19. 2. Prostagl Leukotri Essen Fatty Acids. 55:1996;185-189.
20. 2 induce apoptosis in L1210 cells. FEBS Letters. 321:1993;209-214.
21. 2 in human hepatocarcinoma SK-HEP-1 cells. FEBS Letters. 368:1995;348-352.
22. Atsmon J., Freeman M.L., Meredith M.J., Sweetman B.J., Robers L.J. II. Modulation of the antiproliferative activity of 9 deoxy by conjugation with intracellular glutathione. Adv Prostaglandin Thromboxane Leukotriene Res. 21:1990;887-890.
23. 2. Prostaglandins. 51:1996;413-425.
24. 2 to cisplatin on human ovarian cancer cell growth in nude mice. Eur J Clin Oncol. 24:1988;1829-1833.
25. 2. Cancer Res. 46:1986;3364-3366.
26. 2 in vitro and in vivo. Cancer Res. 46:1986;3538-3542.
27. Kikuchi Y., Kita T., Miyauchi M., Hirata J., Sasa H., Fukushima M. Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude mice bearing human ovarian cancer cells. JCRCO. 118:1992;453-457.
28. Kirkwood J., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H. Interferon alfa-2a adjuvant therapy of high-risk resected cutaneous melanoma the eastern cooperative oncology group trial EST 1684 . J Clin Oncol. 14:1996;7-17.
29. 2. Prostaglandins. 35:1988;277-300.
30. 2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis. 142:1990;126-132.
31. 2. J Bio Chem. 258:1983;11713-11718.
32. 2 in human urine. J Biol Chem. 263:1988;16619-16625.
33. 2 and identification of metabolites in human plasma during intravenous infusion. Prostaglandins. 28:1984;743-754.
34. 2 in man. Prostaglandins. 28:1984;755-767.
35. 2 is cytotoxic in human malignancies and synergizes with cisplatin and radiation. Cancer Res. 56:1996;3866-3869.
36. Mc Clay EF, Jones JA. Characterization of a human melanoma cell line with non-estrogen receptor mediated tamoxifen resistance. Melanoma Research 1999, In press.
37. Mc Clay E.F., Christen R., Albright K.A., Jones J.A., Eastman A., Howell S.B. Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res. 52:1992;6790-6796.
38. Mc Clay E.F., Albright K.A., Jones J.A., Christen R., Howell S.B. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res. 53:1993;1571-1576.
39. Taetle R., Jones O., Honeysett J., Abramson I., Bradshaw C., Reid S. Characterization of xenograft-derived melanoma cell lines. Cancer. 60:1987;1836-1841.
40. Gray-Bablin J., Zalvide J., Fox M.P., Knickerbocker C.J., DeCaprio J.A., Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci. 93:1996;15215-15220.
41. 1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene. 14:1997;295-304.
42. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-b and contact inhibition to cell cycle arrest. Genes Dev. 8:1994;9-22.
43. Reynisdottir I., Polyak K., Iavarone A., Massague J. Kip/Cip and Ink 4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-b. Genes Dev. 9:1995;1831-1856.
44. Hartwell L.H., Kastan M.B. Cell cycle control and cancer. Science. 266:1994;1821-1828.
45. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships the combined effects of multiple drugs or enzyme inhibitors . Adv Enzyme Reg. 22:1986;27-55.
46. Tontonoz P., Singer S., Forman B.M., et al. Terminal Differentiation of human lioposarcoma cells induced by ligands for peroxisome proliferator-activated receptor g and the retinoid X receptor. Proc Natl Acad Sci. 94:1997;237-241.
47. Mueller E., Sarraf P., Tontonoz P., et al. Terminal differentiation of human breast cancer through PPAR g. Mol Cell. 1:1998;465-470.